Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia

Ann Hematol. 2022 Mar;101(3):697-699. doi: 10.1007/s00277-021-04530-y. Epub 2021 May 6.

Jinyu Kong¹, Nan Chen^{1

2}, Mengyun Li¹, Jian Zhang¹, Xiaoxia Wu¹, Lihong Zong¹, Depei Wu^{1

2}, Baoquan Song^{3

4}, Huiying Qiu^{5

6}

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
³ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. songbaoquan@suda.edu.cn.
⁴ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. songbaoquan@suda.edu.cn.
⁵ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. qiuhuiying8303@163.com.
⁶ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. qiuhuiying8303@163.com.

No abstract available

Publication types